Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

What Are the Special Properties of MRSA Prodrug TXA709?

AUG 17, 2017 | CONTAGION® EDITORIAL STAFF


Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, co-founder of TAXIS Pharmaceuticals, explains how the initial drug discovery process for MRSA drug TX709 evolved. The vision was to develop a drug that could be orally bioavailable, but still have a sustained effect. Dr. LaVoie explains how TXA709 has "necessary properties" that allow for it to be formulated for infusion. TXA709 has proved efficacious by the intravenous and oral routes in animal model studies, which offers significant clinical advantages.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x